While the future is still being written, at Aligos we believe we are at the forefront of the next-generation of HBV learnings. Our lead drug candidate, pevifoscorvir sodium, is a CAM-E (Capsid Assembly Modulator) that is purpose-built with the knowledge generated over the past 50+ years. Learn how pevifoscorvir sodium has the potential to block key aspects of the HBV replication cycle in the video below.